Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Elman

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
Radiology|October 19, 2000
Staging evaluation for patients with Hodgkin's disease. American College of Radiology. ACR Appropriateness CriteriaH B Wolkov, A J Elman, R T Hoppe, et al.
JAMA Ophthalmology|July 26, 2018
Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical TrialJeffrey G Gross, Adam R Glassman, Danni Liu, et al.
American Journal of Ophthalmology|February 26, 2008
Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathyNeil M Bressler, Allison R Edwards, Andrew N Antoszyk, et al.
JAMA Ophthalmology|November 26, 2015
Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular EdemaJohn A Wells, Adam R Glassman, Lee M Jampol, et al.
JAMA|November 14, 2015
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial, Jeffrey G Gross, Adam R Glassman, et al.
Journal of Vitreoretinal Diseases|December 10, 2024
Clinical Use of Home OCT Data to Manage Neovascular Age-Related Macular DegenerationJeffrey S Heier, Yingna Liu, Nancy M Holekamp, et al.
The New England Journal of Medicine|February 19, 2015
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema, John A Wells, Adam R Glassman, et al.
JAMA Ophthalmology|May 7, 2013
Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4, Emily Y Chew, John Paul SanGiovanni, et al.
JAMA Ophthalmology|December 7, 2013
Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3, Emily Y Chew, Traci E Clemons, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Radiology|October 19, 2000
Staging evaluation for patients with Hodgkin's disease. American College of Radiology. ACR Appropriateness CriteriaH B Wolkov, A J Elman, R T Hoppe, et al.
JAMA Ophthalmology|July 26, 2018
Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical TrialJeffrey G Gross, Adam R Glassman, Danni Liu, et al.
American Journal of Ophthalmology|February 26, 2008
Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathyNeil M Bressler, Allison R Edwards, Andrew N Antoszyk, et al.
JAMA Ophthalmology|November 26, 2015
Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular EdemaJohn A Wells, Adam R Glassman, Lee M Jampol, et al.
JAMA|November 14, 2015
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial, Jeffrey G Gross, Adam R Glassman, et al.
Journal of Vitreoretinal Diseases|December 10, 2024
Clinical Use of Home OCT Data to Manage Neovascular Age-Related Macular DegenerationJeffrey S Heier, Yingna Liu, Nancy M Holekamp, et al.
The New England Journal of Medicine|February 19, 2015
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema, John A Wells, Adam R Glassman, et al.
JAMA Ophthalmology|May 7, 2013
Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4, Emily Y Chew, John Paul SanGiovanni, et al.
JAMA Ophthalmology|December 7, 2013
Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3, Emily Y Chew, Traci E Clemons, et al.
Pageof 9